Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered. 

 

Topics	Advisory Committee	Date	Details	Biomedtracker Likelihood Of Approval ^1
Research needs for the evaluation of potential adverse health effects in children associated with oral cadmium exposure; cross-cutting regulatory science research activities and the FDA's recent Focus Areas of Regulatory Science report	Science Board	Dec. 8 (teleconference)	Meeting notice
Cytokinetics' omecamtiv mecarbil to reduce the risk of cardiovascular death and heart failure events in patients with symptomatic chronic heart failure with reduced ejection fraction	Cardiovascular and Renal Drugs	Dec. 13 (teleconference)	Meeting notice	84%
Regeneron Pharmaceuticals' supplemental biologics license application for aflibercept solution for intravitreal injection, submitted in response to FDA’s pediatric written request for studies in the treatment of retinopathy of prematurity	Dermatologic and Ophthalmic Drugs	Jan. 9 (teleconference)	Meeting notice	79%
Cidara Therapeutics' rezafungin lyophilized powder for injection for treatment of candidemia and invasive candidiasis in adults	Antimicrobial Drugs	Jan. 24 (teleconference)	Meeting notice	99%
^1 Biomedtracker LOA as of Dec. 2, 2022